Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinomaYuki Nemoto, Toshio Takagi, Hiroki Ishihara et al.|International Urology and Nephrology|2021Cited by 18
Association of tumor burden with outcome in first-line therapy with nivolumab plus ipilimumab for previously untreated metastatic renal cell carcinomaHiroki Ishihara, Toshio Takagi, Tsunenori Kondo et al.|Japanese Journal of Clinical Oncology|2021Cited by 15
Prognostic Impact of Early Treatment Interruption of Nivolumab Plus Ipilimumab Due to Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Multi-Institution Retrospective StudyHiroki Ishihara, Kazunari Tanabe, Yuki Nemoto et al.|Targeted Oncology|2021Cited by 9
Comparison of the Impact of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Dual Combination Therapy and Immune Checkpoint Inhibitor Plus Tyrosine Kinase Inhibitor Combination Therapy in Patients with Advanced Renal Cell CarcinomaHiroki Ishihara, Toshio Takagi, Yuki Nemoto et al.|Targeted Oncology|2022Cited by 8
Efficacy and safety of nivolumab plus cabozantinib in octogenarian patients with advanced renal cell carcinomaYuki Nemoto, Tsunenori Kondo, Takanori Endo et al.|Research Square|2024Cited by 0